BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19900134)

  • 1. COX-2 expression in uterine carcinosarcoma.
    Menczer J; Schreiber L; Sukmanov O; Kravtsov V; Berger E; Golan A; Levy T
    Acta Obstet Gynecol Scand; 2010; 89(1):120-5. PubMed ID: 19900134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
    Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
    Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
    Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
    Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-kit in uterine carcinosarcoma.
    Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
    Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
    Semczuk A; Skomra D; Chyzyńska M; Szewczuk W; Olcha P; Korobowicz E
    Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
    Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K
    Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma.
    Sano A; Sakurai S; Kato H; Sakai M; Tanaka N; Inose T; Saito K; Sohda M; Nakajima M; Sakamoto K; Sano T; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Oyama T; Kuwano H
    Anticancer Res; 2009 Aug; 29(8):3375-80. PubMed ID: 19661359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
    Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
    Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure.
    Farley J; Uyehara C; Hashiro G; Belnap C; Birrer M; Salminen E
    Gynecol Oncol; 2004 Feb; 92(2):596-602. PubMed ID: 14766253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of COX-2 and prognostic outcome in uveal melanoma.
    Cryan LM; Paraoan L; Hiscott P; Damato BE; Grierson I; Gray D; Farrell M; Doherty GA; Fitzgerald DJ; O'Brien C
    Curr Eye Res; 2008 Feb; 33(2):177-84. PubMed ID: 18293189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
    Choi HJ; Kim HJ; Choi JH
    Hepatogastroenterology; 2009; 56(91-92):606-9. PubMed ID: 19621664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
    Gynecol Oncol; 1996 Feb; 60(2):271-6. PubMed ID: 8631550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic features of surgical stage I uterine carcinosarcoma.
    Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
    Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Ruangvejvorachai P; Thorner PS; Siriaunkgul S
    Gynecol Oncol; 2009 Jan; 112(1):241-7. PubMed ID: 18977022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
    Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
    Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
    Costa MJ; Guinee D
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.